PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer

European Urology Focus

Volumn 2, Issue 2, 2016, Pages 180-188

  Lotan, Tamara L ^a   Wei, Wei ^b   Morais, Carlos L ^a   Hawley, Sarah T ^c   Fazli, Ladan ^d   Hurtado Coll, Antonio ^d   Troyer, Dean ^e   McKenney, Jesse K ^f   Simko, Jeffrey ^g   Carroll, Peter R ^g   Gleave, Martin ^d   Lance, Raymond ^e   Lin, Daniel W ^h   Nelson, Peter S ^h   Thompson, Ian M ⁱ   True, Lawrence D ^g   Feng, Ziding ^b   Brooks, James D ^j  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Canary Foundation   (United States)

^d VANCOUVER PROSTATE CENTRE   (Canada)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Biomarker; ERG; Immunohistochemistry; Prostatic carcinoma; PTEN; Radical prostatectomy

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR ERG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER TISSUE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SAMPLE SIZE; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

EID: 84969776648     PISSN: None     EISSN: 24054569     Source Type: Journal    
DOI: 10.1016/j.euf.2015.07.005     Document Type: Article

References (44)

1. Taylor B.S., Schultz N., Hieronymus H., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
2. Berger M.F., Lawrence M.S., Demichelis F., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
3. Grasso C.S., Wu Y.M., Robinson D.R., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
4. Barbieri C.E., Baca S.C., Lawrence M.S., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012, 44:685-689.
5. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
6. Steck P.A., Pershouse M.A., Jasser S.A., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362.
7. Cairns P., Okami K., Halachmi S., et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997, 57:4997-5000.
8. McMenamin M.E., Soung P., Perera S., Kaplan I., Loda M., Sellers W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999, 59:4291-4296.
9. Halvorsen O.J., Haukaas S.A., Akslen L.A. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003, 9:1474-1479.
10. Verhagen P.C., van Duijn P.W., Hermans K.G., et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 2006, 208:699-707.
11. Bedolla R., Prihoda T.J., Kreisberg J.I., et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007, 13:3860-3867.
12. Schmitz M., Grignard G., Margue C., et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007, 120:1284-1292.
13. Yoshimoto M., Cunha I.W., Coudry R.A., et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007, 97:678-685.
14. Sircar K., Yoshimoto M., Monzon F.A., et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009, 218:505-513.
15. Han B., Mehra R., Lonigro R.J., et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009, 22:1083-1093.
16. Reid A.H., Attard G., Ambroisine L., et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010, 102:678-684.
17. Krohn A., Diedler T., Burkhardt L., et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012, 181:401-412.
18. Lotan T.L., Gurel B., Sutcliffe S., et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2011, 17:6563-6573.
19. Antonarakis E.S., Keizman D., Zhang Z., et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 2012, 118:6063-6071.
20. Chaux A., Peskoe S.B., Gonzalez-Roibon N., et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol 2012, 25:1543-1549.
21. Yoshimoto M., Joshua A.M., Cunha I.W., et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008, 21:1451-1460.
22. Troyer D.A., Jamaspishvili T., Wei W., et al. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate 2015, 75:1206-1215.
23. Krohn A., Freudenthaler F., Harasimowicz S., et al. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Mod Pathol 2014, 27:1612-1620.
24. Gumuskaya B., Gurel B., Fedor H., et al. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion. Prostate Cancer Prostatic Dis 2013, 16:209-215.
25. Bismar T.A., Yoshimoto M., Duan Q., Liu S., Sircar K., Squire J.A. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology 2012, 60:645-652.
26. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
27. Pettersson A., Graff R.E., Bauer S.R., et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012, 21:1497-1509.
28. Pettersson A., Lis R.T., Meisner A., et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst 2013, 105:1881-1890.
29. Carver B.S., Tran J., Gopalan A., et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009, 41:619-624.
30. King J.C., Xu J., Wongvipat J., et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009, 41:524-526.
31. Bismar T.A., Yoshimoto M., Vollmer R.T., et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 2011, 107:477-485.
32. Reid A.H., Attard G., Brewer D., et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod Pathol 2012, 25:902-910.
33. Chen Y., Chi P., Rockowitz S., et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med 2013, 19:1023-1029.
34. Hawley S., Fazli L., McKenney J.K., et al. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol 2013, 20:39-44.
35. Chaux A., Albadine R., Toubaji A., et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 2011, 35:1014-1020.
36. Park K., Tomlins S.A., Mudaliar K.M., et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010, 12:590-598.
37. Brooks J.D., Wei W., Hawley S., et al. Evaluation of ERG and SPINK1 by immunohistochemical staining and clinicopathological outcomes in a multi-institutional radical prostatectomy cohort of 1067 patients. PLoS One 2015, 10:e0132343.
38. Lotan T., Morais C., Wei W., et al. PTEN status determination in prostate cancer: comparison of IHC and FISH in a large multi-center cohort. Mod Pathol 2015, 28:241A.
39. Heselmeyer-Haddad K.M., Berroa Garcia L.Y., Bradley A., et al. Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis. Am J Pathol 2014, 184:2671-2686.
40. Steurer S., Mayer P.S., Adam M., et al. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. Eur Urol 2014, 66:978-981.
41. Leinonen K.A., Saramaki O.R., Furusato B., et al. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev 2013, 22:2333-2344.
42. Fontugne J., Lee D., Cantaloni C., et al. Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. Cancer Epidemiol Biomarkers Prev 2014, 23:594-600.
43. Cuzick J., Yang Z.H., Fisher G., et al. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer 2013, 108:2582-2589.
44. Cooperberg M.R., Davicioni E., Crisan A., Jenkins R.B., Ghadessi M., Karnes R.J. combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 2015, 67:326-333.